OfficeHours

JULY 18, 2023

In this industry, owning 50 to 100 or more veterinary centers gives you procurement advantages in that you can buy much higher volumes of suppliers (syringes, medical equipment, etc.) More specifically, this might entail negotiating transaction features such as earn-outs, deferred consideration, or seller financing, just to name a few.

Private Equity 130

Private Equity Equities Investment Mergers and Acquisitions 130

Focus Investment Banking

JUNE 13, 2023

according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. In addition to negotiated payments, providers can earn incentives for providing high-quality, efficient care. Founded in 2007, publicly-traded TOI provides care to about 1.8

Hospitality 52

Hospitality Private Equity Mergers and Acquisitions Medical 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. Of the 20 largest public deals in the healthcare sector in 2021, 14 featured all?cash

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

The rules are expected to increase the frequency of proxy contests (particularly by less-established activists), afford dissidents increased leverage in settlement negotiations, and increase focus on the strength and qualifications of individual directors.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

Public company deals: Smaller bites in more focused therapeutic areas The landscape for public company sales in the life sciences sector in 2024 was notably quieter than expected, with anticipated high-profile deals failing to materialize. Similarly, Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64